Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Stemline Therapeutics, Inc. (STML) Starts Presentation at 25th Annual ROTH Conference

Posted on March 20, 2013 by Mission IR

Stemline Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. STML is developing two clinical-stage product candidates for which it holds global marketing rights: SL-401 for the treatment of myeloid leukemia; and SL-701, for pediatric and adult brain cancer. The company’s StemScreen platform is designed for the discovery of CSC-targeted compounds. For more information, visit the company’s Web site: http://www.stemline.com

Let us hear your thoughts below:

This year's annual ROTH Conference will take place at The Ritz Carlton located in Laguna Niguel, on March 17-12, 2013. Bringing together executives from more than 400 growth companies, the ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com.
This entry was posted in ROTH Capital Partners Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *